◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › AZN

AstraZeneca PLC (AZN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · DATA UPDATED 2026-09-19

AstraZeneca PLC (AZN) operates in the DRUG MANUFACTURERS - GENERAL industry and is headquartered in Cambridge, United Kingdom with about 96,100 employees. Its market capitalization is roughly $258 billion. In the fiscal year ended 2025-12-31, AZN reported $58.7B in revenue and $10.3B in net income.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

Interactive charts & full statements → Open the AZN valuation workbench →

AZN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$61.4B	$58.7B	$54.1B	$45.8B	$44.4B	$37.4B	$26.6B	$24.4B	$22.1B	$22.5B	$23.0B	$24.7B	$26.5B	$25.8B	$28.0B	$33.6B	$33.3B	$32.8B	$31.6B	$29.6B	$26.5B
Gross Profit	$50.2B	$48.1B	$43.9B	$37.5B	$32.0B	$25.0B	$21.3B	$19.5B	$17.2B	$18.1B	$18.9B	$20.1B	$20.7B	$20.5B	$22.6B	$27.6B	$26.9B	$27.0B	$25.0B	$23.1B	$20.9B
Gross Margin %	81.9%	81.9%	81.1%	82.0%	72.1%	66.8%	80.1%	79.8%	77.7%	80.8%	82.1%	81.2%	78.0%	79.6%	80.7%	82.1%	80.8%	82.4%	79.1%	78.3%	79.0%
Operating Income (EBIT)	$14.0B	$13.7B	$10.0B	$8.2B	$3.8B	$1.1B	$5.2B	$2.9B	$3.4B	$3.7B	$4.9B	$4.1B	$2.1B	$3.7B	$8.1B	$12.8B	$11.5B	$11.5B	$9.1B	$8.1B	$8.2B
Operating Margin %	22.8%	23.4%	18.5%	17.9%	8.5%	2.8%	19.4%	12.0%	15.3%	16.4%	21.3%	16.7%	8.1%	14.4%	29.1%	38.1%	34.5%	35.2%	28.9%	27.4%	31.0%
Net Income	$10.4B	$10.3B	$7.0B	$6.0B	$3.3B	$112M	$3.2B	$1.3B	$2.2B	$3.0B	$3.5B	$2.8B	$1.2B	$2.6B	$6.2B	$9.9B	$8.1B	$7.5B	$6.1B	$5.6B	$6.0B
Net Margin %	17.0%	17.5%	13.0%	13.0%	7.4%	0.3%	12.0%	5.5%	9.8%	13.4%	15.2%	11.4%	4.6%	9.9%	22.3%	29.5%	24.2%	22.9%	19.3%	18.9%	22.8%
EBITDA	—	$19.8B	$15.4B	$13.4B	$9.1B	$5.1B	$8.1B	$6.7B	$7.1B	$6.6B	$7.3B	$7.0B	$5.5B	$8.3B	$10.7B	$15.4B	$14.7B	$13.9B	$12.6B	$9.9B	$9.6B
Earnings Per Share (EPS)	$6.69	$6.57	$4.50	$3.81	$2.11	$0.16	$4.87	$2.05	$3.40	$4.74	$5.53	$4.47	$1.95	$4.08	$9.87	$14.51	$11.14	$10.37	$8.40	$7.47	$7.70
Shares Outstanding (M)	—	1,562M	1,563M	1,562M	1,560M	714M	656M	650M	634M	634M	633M	632M	632M	627M	632M	684M	723M	725M	726M	749M	785M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AZN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$15.4B	$15.3B	$15.5B	$15.2B	$14.5B	$13.6B	$14.9B	$13.6B	$12.9B
Gross Profit	$12.9B	$12.6B	$12.4B	$12.4B	$12.0B	$11.3B	$12.2B	$10.5B	$10.8B
Gross Margin %	83.6%	82.5%	79.9%	81.6%	82.9%	83.5%	81.7%	77.3%	83.1%
Operating Income (EBIT)	$3.2B	$4.2B	$3.0B	$3.6B	$3.5B	$3.7B	$2.0B	$2.1B	$2.7B
Operating Margin %	20.6%	27.8%	19.2%	23.6%	24.3%	27.0%	13.7%	15.5%	21.2%
Net Income	$2.5B	$3.1B	$2.3B	$2.5B	$2.5B	$2.9B	$1.5B	$1.4B	$1.9B
Net Margin %	16.3%	20.2%	15.0%	16.7%	17.0%	21.5%	10.1%	10.5%	14.9%
EBITDA	—	$5.7B	$4.6B	$5.2B	$5.0B	$5.0B	$2.8B	$4.1B	$4.1B
Earnings Per Share (EPS)	$1.61	$1.97	$1.49	$1.62	$1.57	$3.74	$1.92	$1.83	$2.47
Shares Outstanding (M)	—	1,561M	1,562M	1,561M	1,559M	780M	781M	780M	780M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AZN Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$13.8B	$14.6B	$11.9B	$10.3B	$9.8B	$6.0B	$4.8B	$3.0B	$2.6B	$3.6B	$4.1B	$3.3B	$7.1B	$7.4B	$6.9B	$7.8B	$10.7B	$11.7B	$8.7B	$7.5B	$7.7B
Capital Expenditures (CapEx)	$7.4B	$5.9B	$4.6B	$3.8B	$2.6B	$2.2B	$2.6B	$2.5B	$1.4B	$1.6B	$2.3B	$2.8B	$2.8B	$2.1B	$4.6B	$1.3B	$2.4B	$3.0B	$4.0B	$1.7B	$1.3B
Free Cash Flow (FCF)	$6.4B	$8.7B	$7.3B	$6.6B	$7.2B	$3.8B	$2.2B	$509M	$1.2B	$2.0B	$1.8B	$536M	$4.3B	$5.3B	$2.3B	$6.5B	$8.3B	$8.8B	$4.7B	$5.8B	$6.4B
FCF Margin %	10.4%	14.8%	13.5%	14.3%	16.3%	10.1%	8.2%	2.1%	5.7%	8.7%	8.0%	2.2%	16.2%	20.7%	8.3%	19.4%	24.8%	26.8%	14.9%	19.7%	24.0%
Dividends Paid	—	$5.0B	$4.6B	$4.5B	$4.4B	$3.9B	$3.6B	$3.6B	$3.5B	$3.5B	$3.6B	$3.5B	$3.5B	$3.5B	$3.7B	$3.8B	$3.4B	$3.0B	$2.7B	$2.6B	$2.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AZN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$2.9B	$3.4B	$2.4B	$5.1B	$3.4B	$3.7B	$2.9B	$3.4B	$3.1B
Capital Expenditures (CapEx)	$3.1B	$1.5B	$1.1B	$1.7B	$1.9B	$969M	$955M	$1.4B	$668M
Free Cash Flow (FCF)	($240M)	$1.8B	$1.4B	$3.4B	$1.5B	$2.7B	$2.0B	$2.0B	$2.4B
FCF Margin %	-1.6%	11.9%	8.9%	22.4%	10.1%	20.2%	13.1%	14.9%	18.7%
Dividends Paid	—	$3.3B	$12M	$1.6B	$10M	$3.3B	$3M	$1.6B	$17M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AZN Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$115.8B	$114.1B	$104.0B	$101.1B	$96.5B	$105.4B	$66.7B	$61.4B	$60.7B	$63.4B	$62.5B	$60.1B	$58.6B	$55.9B	$53.5B	$52.8B	$56.1B	$54.9B	$47.0B	$48.0B	$29.9B
Cash & Cash Equivalents	$4.9B	$5.7B	$5.5B	$5.8B	$6.2B	$6.3B	$7.8B	$5.4B	$4.8B	$3.3B	$5.0B	$6.2B	$6.4B	$9.2B	$7.7B	$7.6B	$11.1B	$9.9B	$4.3B	$5.9B	$7.1B
Total Liabilities	$65.5B	$65.4B	$63.2B	$62.0B	$59.4B	$66.1B	$51.1B	$46.8B	$46.6B	$46.7B	$45.9B	$41.6B	$38.9B	$32.6B	$29.6B	$29.4B	$32.7B	$34.1B	$30.9B	$33.0B	$14.5B
Total Debt (Short + Long-Term)	$32.2B	$28.3B	$29.0B	$27.8B	$28.4B	$29.9B	$2.4B	$2.0B	$1.8B	$2.3B	$2.3B	$925M	$2.5B	$1.8B	$901M	$2.0B	$125M	$1.9B	$993M	$4.3B	$136M
Total Shareholders' Equity	$50.3B	$48.7B	$40.8B	$39.1B	$37.0B	$39.3B	$15.6B	$13.1B	$12.5B	$15.0B	$14.9B	$18.5B	$19.6B	$23.2B	$23.7B	$23.2B	$23.2B	$20.7B	$15.9B	$14.8B	$15.3B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AZN viewer.

AZN Metric Deep Dives

Other Companies in DRUG MANUFACTURERS - GENERAL

NVS · Novartis AG ADR — $267 billion
NVO · Novo Nordisk A/S — $191 billion
SNY · Sanofi ADR — $102 billion
GSK · GlaxoSmithKline PLC ADR — $101 billion
GRFS · Grifols SA ADR — $5 billion
OGN · Organon & Co — $4 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← AZIO All “A” companies AZO →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.